Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial
Haidar et al., The Lancet Infectious Diseases, doi:10.1016/S1473-3099(24)00804-1
https://c19early.org/haidar.html